12-Nov-2025 7:00 AM CST - Business Wire Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported financial results for the third quarter ended September 30, 2025, and provided a corporate update. We believe that the proposed transaction with BioCryst provides the best opportunity to advance navenibart, enabling people with HAE to potentially live free from the limitations of their disease, said Ji
14-Oct-2025 6:00 AM CST - Business Wire BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) and Astria Therapeutics, Inc. (Nasdaq: ATXS) today announced that the companies have entered into a definitive agreement under which BioCryst has agreed to acquire Astria, a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, for a mix of cash and stock representing an implied value of $13.00 per Astria share, and approximately $700 mi
27-Aug-2025 7:00 AM CST - Business Wire Astria Therapeutics to Present at Upcoming Cantor Global Healthcare Conference Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Cantor Global Healthcare Conference on Thursday, September 4 at 3:20pm ET. A webcast of the presentation can be accessed at the following link: https://sqps.onstreamsecure.com/origin/enliven/players/E
12-Aug-2025 3:10 PM CST - Business Wire Astria Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported financial results for the second quarter ended June 30, 2025, and provided a corporate update. Delivering on navenibart's best-in-class potential is our top priority, and enrollment in the global Phase 3 ALPHA-ORBIT trial is well underway with active sites across the U.S., U.K., Canada, Hong Kong, and S
28-May-2025 7:00 AM CST - Business Wire Astria Therapeutics to Present at Upcoming Jefferies Global Healthcare Conference Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Jefferies Global Healthcare Conference on Wednesday, June 4th at 1:25pm ET. A webcast of the presentation can be accessed at the following link: https://wsw.com/webcast/jeff319/atxs/1878784. An archiv
13-May-2025 3:10 PM CST - Business Wire Astria Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported financial results for the first quarter ended March 31, 2025, and provided a corporate update. As a late-stage clinical company, we are focused on delivering on navenibart, a therapy with a trusted mechanism and modality, best-in-class profile, and the potential to change the way that people live with H
30-Apr-2025 7:00 AM CST - Business Wire Astria Therapeutics to Present at Upcoming Citizens Life Sciences Conference Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Citizens Life Sciences Conference on Wednesday, May 7th at 10:30am ET. A webcast of the presentation can be accessed at the following link: https://wsw.com/webcast/jmp65/atxs/1702976. An archived repl
11-Mar-2025 7:00 AM CST - Business Wire Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a corporate update. 2025 promises to be an exciting year for Astria, and we are building on the momentum from a successful 2024 with the initiation of two important clinical trials, said Jill C. Milne, Ph.D., C
25-Feb-2025 7:00 AM CST - Business Wire Astria Therapeutics to Present at Upcoming TD Cowen 45th Annual Health Care Conference Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming TD Cowen 45th Annual Health Care Conference on Tuesday, March 4th at 9:50am ET in Boston, MA. A webcast of the presentation can be accessed at the following link: https://wsw.com/webcast/cowen177/atxs
12-Nov-2025 7:00 AM CST - Business Wire Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported financial results for the third quarter ended September 30, 2025, and provided a corporate update. We believe that the proposed transaction with BioCryst provides the best opportunity to advance navenibart, enabling people with HAE to potentially live free from the limitations of their disease, said Ji
14-Oct-2025 6:00 AM CST - Business Wire BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) and Astria Therapeutics, Inc. (Nasdaq: ATXS) today announced that the companies have entered into a definitive agreement under which BioCryst has agreed to acquire Astria, a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, for a mix of cash and stock representing an implied value of $13.00 per Astria share, and approximately $700 mi
27-Aug-2025 7:00 AM CST - Business Wire Astria Therapeutics to Present at Upcoming Cantor Global Healthcare Conference Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Cantor Global Healthcare Conference on Thursday, September 4 at 3:20pm ET. A webcast of the presentation can be accessed at the following link: https://sqps.onstreamsecure.com/origin/enliven/players/E
12-Aug-2025 3:10 PM CST - Business Wire Astria Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported financial results for the second quarter ended June 30, 2025, and provided a corporate update. Delivering on navenibart's best-in-class potential is our top priority, and enrollment in the global Phase 3 ALPHA-ORBIT trial is well underway with active sites across the U.S., U.K., Canada, Hong Kong, and S
28-May-2025 7:00 AM CST - Business Wire Astria Therapeutics to Present at Upcoming Jefferies Global Healthcare Conference Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Jefferies Global Healthcare Conference on Wednesday, June 4th at 1:25pm ET. A webcast of the presentation can be accessed at the following link: https://wsw.com/webcast/jeff319/atxs/1878784. An archiv
13-May-2025 3:10 PM CST - Business Wire Astria Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported financial results for the first quarter ended March 31, 2025, and provided a corporate update. As a late-stage clinical company, we are focused on delivering on navenibart, a therapy with a trusted mechanism and modality, best-in-class profile, and the potential to change the way that people live with H
30-Apr-2025 7:00 AM CST - Business Wire Astria Therapeutics to Present at Upcoming Citizens Life Sciences Conference Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Citizens Life Sciences Conference on Wednesday, May 7th at 10:30am ET. A webcast of the presentation can be accessed at the following link: https://wsw.com/webcast/jmp65/atxs/1702976. An archived repl
11-Mar-2025 7:00 AM CST - Business Wire Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a corporate update. 2025 promises to be an exciting year for Astria, and we are building on the momentum from a successful 2024 with the initiation of two important clinical trials, said Jill C. Milne, Ph.D., C
25-Feb-2025 7:00 AM CST - Business Wire Astria Therapeutics to Present at Upcoming TD Cowen 45th Annual Health Care Conference Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming TD Cowen 45th Annual Health Care Conference on Tuesday, March 4th at 9:50am ET in Boston, MA. A webcast of the presentation can be accessed at the following link: https://wsw.com/webcast/cowen177/atxs
